Compare iShares Global Tech ETF (IXN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Neurocrine Biosciences Inc — how do they compare? iShares Global Tech ETF trades at $139.33, while Neurocrine Biosciences Inc trades at $161.12 (market cap $16.46B). The key difference: iShares Global Tech ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| IXN | NBIX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $149.74 | $185.50 |
52-Week Low | $94.42 | $123.10 |
Market Cap | — | $16.46B |
Enterprise Value | — | $16.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN trades at $140.87, up 1.09% today, with a bullish technical signal from moving averages. The stock is near resistance at $141, with RSI indicating potential overbought conditions. Recent news highlights its global tech exposure, including AI developments from international firms.
Outlook is cautious due to high valuations and concentration risk in tech holdings. Opportunities exist from AI growth, but risks include stretched earnings expectations and market volatility. Analyst sentiment is mixed, favoring a hold rating for a better entry point.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
